DK1066049T3 - Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse - Google Patents

Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse

Info

Publication number
DK1066049T3
DK1066049T3 DK99910418T DK99910418T DK1066049T3 DK 1066049 T3 DK1066049 T3 DK 1066049T3 DK 99910418 T DK99910418 T DK 99910418T DK 99910418 T DK99910418 T DK 99910418T DK 1066049 T3 DK1066049 T3 DK 1066049T3
Authority
DK
Denmark
Prior art keywords
peptides
preparation
methods
pharmaceutical compositions
sustained release
Prior art date
Application number
DK99910418T
Other languages
Danish (da)
English (en)
Inventor
Marc Pellet
Frederic Bismuth
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Application granted granted Critical
Publication of DK1066049T3 publication Critical patent/DK1066049T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK99910418T 1998-03-25 1999-03-22 Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse DK1066049T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9803667A FR2776520B1 (fr) 1998-03-25 1998-03-25 Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
PCT/FR1999/000667 WO1999048517A1 (fr) 1998-03-25 1999-03-22 Compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation

Publications (1)

Publication Number Publication Date
DK1066049T3 true DK1066049T3 (da) 2003-09-29

Family

ID=9524472

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99910418T DK1066049T3 (da) 1998-03-25 1999-03-22 Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse

Country Status (19)

Country Link
US (1) US6503534B1 (de)
EP (1) EP1066049B1 (de)
JP (1) JP4162381B2 (de)
AR (1) AR020062A1 (de)
AT (1) ATE241377T1 (de)
AU (1) AU756148B2 (de)
CA (1) CA2324901C (de)
CZ (1) CZ298941B6 (de)
DE (1) DE69908326T2 (de)
DK (1) DK1066049T3 (de)
ES (1) ES2200507T3 (de)
FR (1) FR2776520B1 (de)
HU (1) HU228903B1 (de)
IL (2) IL138533A0 (de)
NO (1) NO324621B1 (de)
PL (1) PL197775B1 (de)
PT (1) PT1066049E (de)
RU (1) RU2224538C2 (de)
WO (1) WO1999048517A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
NZ538928A (en) * 2002-09-27 2006-10-27 Zentaris Gmbh Administration form for pharmaceutically active peptides with sustained release of active ingredient, and method for the production thereof
WO2004087102A2 (en) * 2003-03-26 2004-10-14 Teva Pharmaceutical Industries Ltd. A process for preparing a pharmaceutical active ingredient with high specific surface area
EP3025722B1 (de) 2003-10-03 2020-05-27 Thorn BioScience, LLC Verfahren zur synchronisierung der ovulation für zeitlich angepasstes brüten ohne hitzenachweis
CA2550695A1 (en) * 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Glp-1 pharmaceutical compositions
US20090023644A1 (en) * 2004-01-13 2009-01-22 Southard Jeffery L Methods of using cgrp for cardiovascular and renal indications
CA2552677A1 (en) * 2004-01-13 2005-07-28 Vasogenix Pharmaceuticals, Inc. Controlled release cgrp delivery composition for cardiovascular and renal indications
TW200538148A (en) * 2004-01-13 2005-12-01 Vasogenix Pharmaceuticals Inc Methods for treating acute myocardial infarction by administering calcitonin gene related peptide and compositions containing the same
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
GB0511269D0 (en) * 2005-06-02 2005-07-13 Creative Peptides Sweden Ab Sustained release preparation of pro-insulin C-peptide
EP1912724A2 (de) * 2005-07-28 2008-04-23 Global Research Technologies, LLC Entfernung von kohlendioxid aus luft
GB0517627D0 (en) 2005-08-30 2005-10-05 Tyco Electronics Ltd Uk Bus-bar and connector
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8334257B2 (en) 2005-12-20 2012-12-18 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20070219811A1 (en) * 2006-03-16 2007-09-20 Kim John S Method for using an internet-based CRM application to create an on-line leads marketplace
ES2447516T3 (es) * 2006-12-21 2014-03-12 Stryker Corporation Formulaciones de liberación sostenida que comprenden cristales BMP-7
EP2142207A4 (de) * 2007-04-04 2013-01-16 Theratechnologies Inc Pharmazeutische formulierungen von ghrh-molekülen
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
CA2953975C (en) 2008-06-27 2019-11-26 Duke University Therapeutic agents comprising elastin-like peptides
ES2661240T3 (es) 2009-04-23 2018-03-28 Jbs United Animal Health Ii Llc Método y composición para sincronizar el momento de inseminación
KR101795643B1 (ko) 2009-05-01 2017-11-09 훼링 비.브이. 전립선암 치료용 조성물
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
EP2464370B1 (de) 2009-08-14 2017-03-29 Phasebio Pharmaceuticals, Inc. Modifizierte vasoaktive darmpeptide
TWI536999B (zh) * 2010-01-13 2016-06-11 艾普森藥品公司 製備持續釋放生長激素抑制素類似物之醫藥組成物之方法
HUE031113T2 (en) 2010-10-27 2017-06-28 Ferring Bv Procedure for the preparation of Degarelix and its intermediates
EP2447276A1 (de) 2010-10-27 2012-05-02 Ferring B.V. Verfahren zur Herstellung von Degarelix und seinen Zwischenprodukten
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
CN107569456A (zh) 2012-06-01 2018-01-12 辉凌公司 制造地加瑞克
ES2808409T3 (es) 2012-11-28 2021-02-26 United Ah Ii Llc Método para sincronizar el tiempo de inseminación en cerdas primerizas
EP2823808A1 (de) 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmazeutische Zusammensetzung für eine verzögerte Freisetzung von Lanreotid
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
EP2910255A1 (de) * 2014-02-19 2015-08-26 MedSkin Solutions Dr. Suwelack AG Verfahren zur Herstellung von Biopolymeren mit definiertem mittlerem Molekulargewicht
TW201625218A (zh) * 2014-04-18 2016-07-16 Ｊｂｓ聯合動物保健有限責任公司 製造含ｇｎｒｈ凝膠之方法
EP3139949B1 (de) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Zusammensetzungen enthaltend ein vip-elp fusionsprotein zur verwendung in der behandlung von mukoviszidose
US10688156B2 (en) 2015-02-09 2020-06-23 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
WO2020170185A1 (en) * 2019-02-21 2020-08-27 Dr. Reddy’S Laboratories Limited Substantially pure lanreotide or its salt & process thereof
GR1009814B (el) * 2019-07-29 2020-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει ενα πεπτιδιο αναλογο σωματοστατινης
CN110577567A (zh) * 2019-09-03 2019-12-17 杭州诺泰澳赛诺医药技术开发有限公司 一种制备高比表面积活性多肽或蛋白的方法
CN118302211A (zh) * 2021-11-22 2024-07-05 Specgx有限责任公司 可注射缓释药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990013285A1 (en) * 1989-05-01 1990-11-15 Enzytech, Inc. Process for producing small particles of biologically active molecules
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions

Also Published As

Publication number Publication date
EP1066049B1 (de) 2003-05-28
PL197775B1 (pl) 2008-04-30
DE69908326D1 (de) 2003-07-03
PL343005A1 (en) 2001-07-30
HUP0101545A3 (en) 2001-12-28
FR2776520A1 (fr) 1999-10-01
CA2324901C (fr) 2012-01-24
JP4162381B2 (ja) 2008-10-08
FR2776520B1 (fr) 2000-05-05
AU756148B2 (en) 2003-01-02
DE69908326T2 (de) 2004-03-25
US6503534B1 (en) 2003-01-07
CA2324901A1 (fr) 1999-09-30
RU2224538C2 (ru) 2004-02-27
CZ20003432A3 (cs) 2001-02-14
ATE241377T1 (de) 2003-06-15
PT1066049E (pt) 2003-10-31
AR020062A1 (es) 2002-04-10
NO20004741L (no) 2000-11-22
IL138533A (en) 2006-12-31
NO20004741D0 (no) 2000-09-22
IL138533A0 (en) 2001-10-31
ES2200507T3 (es) 2004-03-01
WO1999048517A1 (fr) 1999-09-30
AU2938499A (en) 1999-10-18
NO324621B1 (no) 2007-11-26
HUP0101545A1 (hu) 2001-11-28
HU228903B1 (en) 2013-06-28
EP1066049A1 (de) 2001-01-10
CZ298941B6 (cs) 2008-03-19
JP2002507578A (ja) 2002-03-12

Similar Documents

Publication Publication Date Title
DK1066049T3 (da) Farmaceutiske præparater, der er beregnet til langvarig frigivelse af peptider og fremgangsmåde til fremstilling af disse
DK0980240T3 (da) Sammensætninger med lang frigivelse og fremgangsmåde til fremstilling heraf
DK1275387T3 (da) Fremgangsmåde til fremstilling af farmaceutiske præparater af fenofibrat med höj biologisk tilgængelighed
NO20001409D0 (no) Karboksamidotiazolderivater, fremgangsmåte for fremstilling derav og farmasøytiske blandinger
DK1326585T4 (da) Fremgangsmåde til fremstilling af pulverformuleringer
NO992339D0 (no) Farmas°ytiske formuleringer
DK1042355T3 (da) 11beta-halogen-7alfa-substituerede estratriener, fremgangsmåde til fremstilling af farmaceutiske præparater, der indeholder disse 11beta-halogen-7alfa-substituerede estratriener, samt deres anvendelse til fremstilling af lægemidler
NO20011613L (no) Sammensetninger og fremgangsmåte for WT1-spesifikk immunterapi
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
DK1152765T3 (da) Ethanolat af azithromycin, fremgangsmåde til fremstilling og farmaceutiske sammensætninger deraf
DK1372686T3 (da) Fremgangsmåder og sammensætninger til peptidsyntese
EE200100134A (et) Kiiresti vabastav tablett
DK1202965T3 (da) Indolderivater, fremgangsmåde til fremstilling deraf, farmaceutiske præparater indeholdende disse og deres medicinske anvendelse
DK1181397T3 (da) Rhodium-elektrokatalysator og fremgangsmåde til fremstilling af denne
DK0991654T3 (da) Hidtil ukendte derivater af 2-(iminomethyl)aminophenyl, deres fremstilling, deres anvendelse til medikamenter og farmaceutiske præparater indeholdende samme
DK0973763T3 (da) Hidtil ukendte 2-(iminomethyl)aminophenylderivater, fremstilling af disse, anvendelse af disse i egenskab af lægemidler og farmaceutiske præparater indeholdende disse
DK0977812T3 (da) Asfaltsammensætninger og fremgangsmåder til fremstilling deraf
DK0991415T3 (da) Faste, oralt indgivelige dosisformer for ribavirin og fremgangsmåde til fremstilling af disse
IS2841B (is) Samstæða hluta og lyfjasamsetningar
DK1049721T3 (da) Syntetiske polysaccharider, fremgangsmåde til fremstilling heraf og farmaceutiske præparater indeholdende disse
DK1015433T3 (da) Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-oler, fremgangsmåder til fremstilling af disse og deres anvendelse som lægemidler
NO20022022D0 (no) N-guanidinoalkylamider, deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
NO20016404L (no) Naftyridinderivater, fremgangsmåter for deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
DK1171444T3 (da) Pyridothienodiazepiner, fremgangsmåde til fremstilling af disse og farmaceutiske præparater indeholdende disse
IS6402A (is) Nýjar greinóttar setnar amínó afleiður af 3-amínó-1-fenýl-1H[1,2,4]tríazóli, aðferðir til framleiðslu á þeim og lyfjasamsetningar sem innihalda þær